RxDoctor Payments Data

Laura Brynestad

Acute Care · Cedar Park, TXNPI 1649510785

Payments from drug & device makers

$3,296in general payments, 2019–2025

Across 193 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$887
  • AbbVie$395
  • UCB, Inc.$255
  • Collegium Pharmaceutical, Inc.$201
  • Aurinia Pharma U.S., Inc.$191
  • Redhill Biopharma Inc.$187
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,26999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,296 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$111,934
Medicare patients
306
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine38$9,698
MovantikNaloxegol Oxalate12$4,692
Gabapentin377$4,346
Tramadol Hcl ErTramadol Hcl51$3,233
Pregabalin167$2,939
Lidocaine23$2,915
Celecoxib53$2,068
Tizanidine Hcl169$1,801
Buprenorphine Hcl74$1,285
Duloxetine Hcl70$1,266
Baclofen66$1,137
Tramadol Hcl126$912
Amitriptyline Hcl43$729
Methocarbamol90$672
Cyclobenzaprine Hcl79$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$187$4,69212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →